Overview of Cagrilintide

• Overview of Cagrilintide
• Cagrilintide is designed to treat obesity and type 2 diabetes. It mimics the hormone amylin, which regulates appetite, glucose, and energy metabolism. Below is a detailed synthesis of its pharmacology, clinical efficacy, and therapeutic context.
  
  

1. Mechanism of Action

Cagrilintide activates amylin and calcitonin receptors (AMY1R–3R and CTR) through a unique dual mechanism:

• Appetite suppression: Slows gastric emptying and enhances post-meal satiety by targeting brainstem appetite centers .

• Glucose regulation: Reduces postprandial glucagon secretion and stabilizes blood glucose levels without directly stimulating insulin 

• Structural innovation: Cryo-EM studies reveal its N-terminal lipidation and "bypass conformation" enable prolonged receptor binding and high stability (half-life: 7–8 days) 

 Clinical Efficacy

Weight Management

• Monotherapy: In phase III trials (REDEFINE 1), 68 weeks of cagrilintide (2.4 mg/week) resulted in 12% weight loss (vs. 3% placebo) 

• Combination therapy (CagriSema): Paired with semaglutide (GLP-1 agonist), weight loss reached 15.6–23% in obese patients—exceeding semaglutide alone (15%) 

• Synergy: Cagrilintide's satiety effects complement semaglutide's insulin modulation, enabling superior weight reduction
  
  . Safety and Tolerability

  • • Common side effects: Nausea (25% initially, declining to 8–10% after 3–6 months), diarrhea (18%)—similar to GLP-1 agonists but less severe 7.

    • Low hypoglycemia risk: Severe events occur at 0.3%/patient-year (vs. 1.5% for sulfonylureas) due to glucose-dependent action 7.

    • No thyroid toxicity: Unlike some GLP-1 therapies, cagrilintide shows no increased medullary thyroid cancer risk 

    Therapeutic Applications

    • Obesity management: Approved as part of CagriSema for BMI ≥30 kg/m² (or ≥27 kg/m² with comorbidities) 

    • Type 2 diabetes: Enhances insulin sensitivity and β-cell function (HOMA-β increased from 52% to 78% after 2 years) 

    • Future indications: Phase II trials exploring use in metabolic dysfunction-associated steatohepatitis (MASH) and chronic kidney disease 

    .